Dr. Luis Alberto Dehesa, MD

Dr. Dehesa practices at Pathology Associates in Clovis, California.

Dr. Dehesa's NPI, 1629412259, was assigned on April 25, 2013. Dr. Dehesa graduated from Other in 2004. Dr. Dehesa holds California license A142134.

Dr. Dehesa's primary practice is Pathology Associates, at 305 Park Creek Dr, Clovis, CA 93611 in Fresno County. The practice phone is (559) 326-2800.

Dr. Dehesa's primary practice is Pathology Associates in Clovis, California. The medical group on file is Dehesa Dermatology. Dmand AI also links Dr. Dehesa to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dehesa practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Dehesa's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Dehesa is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Dehesa's licenses on file in 2 states: California and Florida.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, facial skin infection, hives and itchy rashes among the conditions Dr. Dehesa treats.

CMS data shows 6,521 Medicare services from Dr. Dehesa across 34 procedure codes in 2024, for 1,017 Medicare patients. Medicare paid $592,013 for them. Every service was in an office.

CMS counts 1,017 Medicare patients who saw Dr. Dehesa in 2024. The largest group is 65 to 74, with 463 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 52% are also on Medicaid. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Dehesa's median patient age at 63, with 55% women.

In 2024, Dr. Dehesa wrote 2,823 Medicare Part D claims for 688 patients. 84% of them were for generic drugs. CMS names the drug for 2,644 of them, across 36 drugs with 11 or more claims each, at $3,348,360 in total drug cost. In 2023, CMS named 2,201 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Dehesa for performance year 2024, reported as part of a group. Dr. Dehesa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 636 procedures of skin biopsy by Dr. Dehesa, more than 97% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 15 papers to Dr. Dehesa, published from 2011 to 2020. The most frequent topics are Psoriasis, Etanercept and Dermatologic Agents. Dr. Dehesa has published most often in Actas Dermosifiliogr. Dr. Dehesa's most frequent co-authors are Francisco A. Kerdel, MD, Carlos A. Ricotti, MD and Carlos A. Ricotti, MD.

CMS Open Payments shows 171 general payments to Dr. Dehesa from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 94% of the total. Janssen Pharmaceuticals, Inc paid the most, $1,513.

Dr. Dehesa graduated from Other in 2004.

Dr. Dehesa is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.